

China Pharma's Q2 2014 revenue dips by 24%

19 August 2014 | Company results | By BioSpectrum Bureau



Singapore: China Pharma has marked revenue of USD 6.1 million in the second quarter of 2014, sliding down 24 percent from USD 8 million in the second quarter of 2013.

Ms Zhilin Li, chairman and CEO, China Pharma commented that, "We have submitted the application for a new GMP certificate at the end of June 2014. We believe that the GMP upgrading will be successful and expect the new GMP certificate to be issued in approximately three to six months from our submission of the application."